Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

MLA

Enrico Montanari, et al. “Every-Other-Day Interferon Beta-1b versus Once-Weekly Interferon Beta-1a for Multiple Sclerosis: Results of a 2-Year Prospective Randomised Multicentre Study (INCOMIN).” Lancet (London, England), vol. 359, no. 9316, May 2002. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a7f5609dfcbf98146e106344c291a777&authtype=sso&custid=ns315887.

APA

Enrico Montanari, E. Verdun, Mauro Bergui, Mauro Zaffaroni, Angelo Ghezzi, P. Barbero, Elisabetta Versino, & Luca Durelli. (2002). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (London, England), 359(9316).

Chicago

Enrico Montanari, E. Verdun, Mauro Bergui, Mauro Zaffaroni, Angelo Ghezzi, P. Barbero, Elisabetta Versino, and Luca Durelli. 2002. “Every-Other-Day Interferon Beta-1b versus Once-Weekly Interferon Beta-1a for Multiple Sclerosis: Results of a 2-Year Prospective Randomised Multicentre Study (INCOMIN).” Lancet (London, England) 359 (9316). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a7f5609dfcbf98146e106344c291a777&authtype=sso&custid=ns315887.